Actinium Pharmaceuticals, Inc. (ATNM)

Negative net income growth while RVPH stands at 18.67%. Joel Greenblatt would see a comparative disadvantage in bottom-line performance.

D&A growth of 13.04% while RVPH is zero at 0.00%. Bruce Berkowitz would see a mild cost difference that must be justified by expansions.

Deferred tax of 100.00% while RVPH is zero at 0.00%. Bruce Berkowitz would see a partial difference that can matter for future cash flow if large in magnitude.

Both reduce yoy usage, with RVPH at -147.75%. Martin Whitman would find an industry or cyclical factor prompting leaner operational approaches.

Both negative yoy AP, with RVPH at -147.80%. Martin Whitman would find an overall trend toward paying down supplier credit in the niche.

Both reduce yoy usage, with RVPH at -56.86%. Martin Whitman would suspect an industry or cyclical factor pulling back on these items.

Both negative yoy, with RVPH at -102.41%. Martin Whitman would suspect an overall environment of intangible cleanup or shifting revaluations for the niche.

Both yoy CFO lines are negative, with RVPH at -69.52%. Martin Whitman would suspect cyclical or cost factors harming the entire niche’s cash generation.

Negative yoy CapEx while RVPH is 0.00%. Joel Greenblatt would see a near-term FCF boost unless competitor invests for long-term advantage.

No Data available this quarter, please select a different quarter.

We reduce yoy invests while RVPH stands at 0.00%. Joel Greenblatt sees near-term liquidity advantage unless competitor’s expansions yield high returns.

No Data available this quarter, please select a different quarter.

Both yoy lines negative, with RVPH at -100.00%. Martin Whitman suspects an environment or preference for internal financing over new equity in the niche.

No Data available this quarter, please select a different quarter.